Clinical Trial
TRIUMPH-1 completes enrolment ahead of primary readout window
The pivotal obesity study has closed enrolment, with the 72-week primary endpoint expected to report in the coming quarters.
1 Sept 2026
Editorial record
Independent Clinical & Regulatory Intelligence
Retatrutide Intelligence
Clinical trials, research, efficacy, safety and regulatory developments — tracked in one place.
Independent research platform. Not affiliated with Eli Lilly and Company.
Compound Status
Data preview- Compound
- LY3437943
- Stage
- Phase 3
- FDA Approved
- No
- Status
- Investigational
- Developer
- Eli Lilly and Company
- Next Milestone
- Regulatory update
Last verified: Data pending
Primary source: Data pending
- Development stage Unverified
- Phase 3
- Retatrutide intervention trials Verified
- 34
- Latest Efficacy Result Unverified
- Data pending
- Expected Regulatory Filing Verified
- Regulatory update
Database record · 4 Sept 2026
Database record · 4 Sept 2026
Database record · Data pending
Database record · 4 Sept 2026
Status Dashboard
Retatrutide development status
A consolidated view of the compound's development stage, regulatory standing and next expected milestone.
Development Timeline
Last verified: Data pending
- ✓
Discovery
Complete
- ✓
Phase 1
Complete
- ✓
Phase 2
Complete
Phase 3
Current
FDA Submission
Pending
FDA Review
Pending
Approval
Pending
Current stage
Phase 3
Next milestone
Regulatory update
Expected timing
Data pending
Last development
TRIUMPH-1 completes enrolment ahead of primary readout window
Last verified
Data pending
Source
Data pending
Compound Record
- Developer
- Eli Lilly and Company
- Compound
- LY3437943
- Mechanism
- GLP-1 / GIP / Glucagon receptor agonist
- Development Stage
- Phase 3
- FDA Approved
- No
- Regulatory Status
- Investigational
- Next Expected Milestone
- Regulatory update
- Last Updated
- 4 Sept 2026
Efficacy
Latest Retatrutide Data
Headline figures from the most advanced reported dataset, presented for orientation only.
Demo data
Latest Efficacy Result
Data connection pending
Awaiting verified endpoint data from sponsor topline reports
Trial
TRIUMPH-1
Adults with obesity, no type 2 diabetes
Study Duration
72 weeks
Randomised, double-blind treatment period
Participants
2,140
Randomised across all treatment arms
Dose
12 mg weekly
Highest maintenance dose reported
Source
Sponsor topline
Illustrative summary — demo data
Sample figures shown for layout purposes. Verified values, confidence intervals and source citations will be published per trial and per endpoint.
Trial Registry
Retatrutide Clinical Trial Tracker
Registered studies across obesity, type 2 diabetes and related indications, with status and completion timing.
| Trial | ClinicalTrials.gov ID | Indication | Phase | Enrolment | Status | Primary Completion | Last Updated | Verification |
|---|---|---|---|---|---|---|---|---|
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | NCT05445232 | Obesity | Phase 1 | 32 | Completed | 24 Feb 2023 | 4 Sept 2026 | Verified |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | NCT07165028 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 3 | 4,500 | Recruiting | 1 Aug 2030 | 4 Sept 2026 | Verified |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | NCT06003465 | Healthy | Phase 1 | 57 | Completed | 8 Feb 2024 | 4 Sept 2026 | Verified |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | NCT03841630 | Healthy | Phase 1 | 45 | Completed | 25 Jul 2019 | 4 Sept 2026 | Verified |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants | NCT05757531 | Healthy | Phase 1 | 7 | Completed | 23 Jun 2023 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | NCT05548231 | Overweight, Obesity | Phase 1 | 32 | Completed | 27 Jul 2023 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | NCT05611957 | Healthy, Renal Insufficiency | Phase 1 | 29 | Completed | 5 Sept 2023 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Healthy Participants With a High Body Mass Index | NCT05959096 | Healthy | Phase 1 | 85 | Completed | 25 Jul 2024 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | NCT04823208 | Diabetes Mellitus, Type 2 | Phase 1 | 64 | Completed | 23 Jun 2022 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | NCT04881760 | Obesity, Overweight | Phase 2 | 338 | Completed | 16 May 2022 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Participants With Impaired and Normal Liver Function | NCT05916560 | Healthy, Hepatic Insufficiency | Phase 1 | 43 | Completed | 2 Mar 2025 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Participants With Type 2 Diabetes | NCT04867785 | Type 2 Diabetes | Phase 2 | 281 | Completed | 8 Jul 2022 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | NCT04143802 | Diabetes Mellitus, Type 2 | Phase 1 | 72 | Completed | 28 Dec 2020 | 4 Sept 2026 | Verified |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | NCT06039826 | Overweight | Phase 1 | 46 | Completed | 11 Jul 2024 | 4 Sept 2026 | Verified |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | NCT05936151 | Overweight or Obesity, CKD, Type 2 Diabetes | Phase 2 | 146 | Completed | 1 Oct 2025 | 4 Sept 2026 | Verified |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | NCT06982859 | Diabetes Mellitus, Insulin Sensitivity | Phase 1 | 95 | Active, not recruiting | 1 Dec 2026 | 4 Sept 2026 | Verified |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | NCT06982846 | Type 2 Diabetes Mellitus | Phase 1 | 80 | Completed | 4 May 2026 | 4 Sept 2026 | Verified |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | NCT06313528 | Obesity | Phase 1 | 85 | Completed | 26 Aug 2025 | 4 Sept 2026 | Verified |
| BICEP | NCT07226947 | Obesity, Body Composition | Not applicable | 100 | Recruiting | 1 Jun 2027 | 4 Sept 2026 | Verified |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | NCT06354660 | Diabetes Type 2 | Phase 3 | 537 | Completed | 22 Jan 2026 | 4 Sept 2026 | Verified |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | NCT06297603 | Type 2 Diabetes | Phase 3 | 320 | Active, not recruiting | 1 Oct 2026 | 4 Sept 2026 | Verified |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | NCT06260722 | Diabetes Mellitus, Type 2 | Phase 3 | 1,250 | Active, not recruiting | 1 Aug 2026 | 4 Sept 2026 | Verified |
| GZBF | NCT07467447 | Obesity | Phase 2 | 300 | Recruiting | 14 Mar 2027 | 4 Sept 2026 | Verified |
| Pre-approval Expanded Access of Retatrutide (LY3437943) | NCT07629401 | Obesity, Obesity-related Complications | Data pending | Data pending | Available | Data pending | 4 Sept 2026 | Verified |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | NCT06383390 | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | Phase 3 | 10,000 | Active, not recruiting | 1 Feb 2029 | 4 Sept 2026 | Verified |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | NCT06808802 | Healthy | Phase 1 | 30 | Completed | 15 Apr 2025 | 4 Sept 2026 | Verified |
| TRANSCEND-T2D | NCT05951192 | Type 2 diabetes glycaemic control | Phase 2 | 540 | Completed | 31 Mar 2026 | 4 Sept 2026 | Unverified |
| TRIUMPH-1 | NCT05929066 | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | Phase 3 | 2,335 | Completed | 6 Apr 2026 | 4 Sept 2026 | Verified |
| TRIUMPH-2 | NCT05929079 | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | Phase 3 | 1,152 | Completed | 16 Jun 2026 | 4 Sept 2026 | Verified |
| TRIUMPH-3 | NCT05882045 | Obesity, Cardiovascular Diseases | Phase 3 | 1,946 | Completed | 16 Apr 2026 | 4 Sept 2026 | Verified |
| TRIUMPH-4 | NCT05931367 | Obesity, Overweight, Osteo Arthritis Knee | Phase 3 | 445 | Completed | 14 Nov 2025 | 4 Sept 2026 | Verified |
| TRIUMPH-5 | NCT06662383 | Obesity | Phase 3 | 800 | Active, not recruiting | 1 Nov 2026 | 4 Sept 2026 | Verified |
| TRIUMPH-6 | NCT06859268 | Obesity | Phase 3 | 643 | Active, not recruiting | 1 Apr 2028 | 4 Sept 2026 | Verified |
| TRIUMPH-7 | NCT07035093 | Obesity, Overweight, Chronic Low Back Pain (CLBP) | Phase 3 | 586 | Active, not recruiting | 1 Sept 2027 | 4 Sept 2026 | Verified |
| TRIUMPH-8 | NCT07232719 | Obesity, Overweight | Phase 3 | 250 | Active, not recruiting | 1 Jul 2027 | 4 Sept 2026 | Verified |
| TRIUMPH-9 | NCT07357415 | Obesity, Overweight | Phase 3 | 600 | Active, not recruiting | 1 Oct 2028 | 4 Sept 2026 | Verified |
Records are shown exactly as stored in the Retatrutide Report database. A record is marked verified only once a source and a verification timestamp have been recorded.
Regulatory
Retatrutide FDA Approval Tracker
Progress through the United States regulatory sequence. Stages advance only when an official FDA record has been detected and confirmed against its source document.
Phase 3 programme
14 verified Phase 3 registry records
FDA submission
Not confirmed by an official source
Filing acceptance
Not confirmed by an official source
FDA review
Not confirmed by an official source
FDA decision
Not confirmed by an official source
Commercial launch
Not confirmed by an official source
- Current confirmed stage
- Phase 3 programme
- Latest official development
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- Development date
- 12 Aug 2026
- Source
- Eli Lilly and Company — https://investor.lilly.com/news-releases/news-release-details/lilly-calls-online-platforms-payment-companies-and-regulators
- Last source check
- 4 Sept 2026
- Approval status
- Not approved by the FDA
Developments
Latest Retatrutide Developments
Official FDA, EMA and Eli Lilly disclosures detected by automated source monitoring, alongside editorial records. Every entry links to its source document.
Read Analysis
Regulatory
What retatrutide's regulatory pathway could look like
An analysis of the filings, endpoints and outcome data that typically precede a submission for an obesity indication.
26 Aug 2026
Editorial record
Research
Review examines glucagon receptor contribution to weight loss
Investigators assess how the glucagon arm of triple agonism may add to energy expenditure beyond incretin effects.
22 Aug 2026
Editorial record
Safety
Gastrointestinal events remain the most frequently reported findings
Nausea, vomiting and constipation dominate reported adverse events, mostly mild to moderate and dose-escalation related.
16 Aug 2026
Editorial record
Eli Lilly and Company
criticalLilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S.
12 Aug 2026
Detected from official source — editorial confirmation pending
Efficacy
Dose-response signal persists at the highest maintenance doses
Reported weight-change curves had not clearly plateaued at the end of the treatment period in earlier-phase studies.
10 Aug 2026
Editorial record
Preview Tool
Retatrutide Results Explorer
Filter reported efficacy and tolerability endpoints by trial, dose and treatment duration. Selections are illustrative in this preview.
Demo data — preview
Mean Weight Change
All values are demonstration data used to prototype the explorer interface. Verified endpoint data, analysis populations and citations will replace them.
Literature
Latest Retatrutide Research
Peer-reviewed publications covering pharmacology, efficacy and safety of retatrutide.
Mechanistic / preclinical researchPMID 42385950
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Keskin U, Altın E, Kara MK, Tekin B, Çakırçoban KN, Özatik FY, Arı NS, Sezgin AK, Güngor E
Behavioural brain research · 2 Oct 2026
Key finding
Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has shown strong metabolic efficacy, but its effects on diabetes-associated cognitive dysfunction remain unclear. The present study investigated whether Retatruti
Mechanistic / preclinical researchPMID 42630988
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Ding M, Li X, Wei Y, Wang J, Jiao B, Li C, Ma W, Peng Y, Shen J, Yu G, Gao C
iScience · 18 Sept 2026
Key finding
Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models. Integrating in vivo and in vitro data showed model- and drug-specific patterns
ReviewPMID 42673585
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Moiz A, Filion KB, Samuels AE, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ
Annals of internal medicine · 1 Sept 2026
Key finding
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management. PURPOSE: To update our prior systematic review evaluating the efficacy and safety of GLP-1 RAs and co-agonists among adults with overweight or obesity without diabetes. DATA SOURCES: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from 5 October 2024 through 25 March
Editorial / commentaryPMID 42559975
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.
Piatkowski T, Craven A, Cornell S, Ferris J
Drug and alcohol review · 1 Sept 2026
Key finding
Data pending
ReviewPMID 42683980
Pharmacological management of obesity: Current landscape and emerging therapies.
Atal S, Agrawal C, Gupta R, Sadasivam B
Indian journal of pharmacology · 1 Sept 2026
Key finding
Obesity is now recognized as a chronic, multifactorial, and progressive disease as opposed to mere excess of body weight. It significantly increases the risk of type 2 diabetes, cardiovascular disease, metabolic-associated fatty liver disease, and mental health disorders. 2022 data reveal that nearly 3 billion individuals worldwide were living with either obesity or overweight. Pharmacological the
ReviewPMID 42556625
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
Roskoski R
Pharmacological research · 1 Sept 2026
Key finding
Owing to the therapeutic success of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists in the management of diabetes and obesity, the pharmacology of these drugs and their receptors has engendered considerable interest. GLP-1 and GIP are incretin hormones so named owing to their ability to increase insulin secretion. Currently FDA-ap
Primary clinical researchPMID 42682157
Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.
Kim Y, Lee EY, Korean Diabetic Kidney Disease Study Group
Kidney research and clinical practice · 1 Sept 2026
Key finding
Obesity and type 2 diabetes (T2D) are dominant drivers of chronic kidney disease (CKD) within the cardio-kidney-metabolic (CKM) syndrome. Despite advances with renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors, substantial residual cardiovascular and renal risk persists, highlighting the need for therapies targeting upstream metabolic dysfunction. Glucagon-l
OtherPMID 42649514
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.
Koca N, Uyar S, Şahintürk Y, Yıldız H, Del Prato S, DeFronzo R
Cardiovascular diabetology · 26 Aug 2026
Key finding
The traditional glucose-centric paradigm of type 2 diabetes management is being superseded by growing evidence that certain agents, sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and pioglitazone, confer cardiovascular, renal, and hepatic benefits that extend well beyond glycemic control. Building on the previously proposed "diabetes/diseas
Primary clinical researchPMID 42608321
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ
Diabetes, obesity & metabolism · 17 Aug 2026
Key finding
AIMS: To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). MATERIALS AND METHODS: Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials. In Study 1, adults with obesity/overweight and T2D
OtherPMID 42567543
Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.
Brown C
BMJ (Clinical research ed.) · 7 Aug 2026
Key finding
Data pending
Primary clinical researchPMID 42562129
Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
Narla S, Narla RR
Clinics in dermatology · 6 Aug 2026
Key finding
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly expanded beyond the treatment of type 2 diabetes mellitus (T2DM) and obesity, with increasing relevance to dermatologic practice as more patients present while receiving these therapies. This medication class now includes oral formulations including oral semaglutide and the first non-peptide oral GLP-1RA, orforglipron as well as nex
ReviewPMID 42590128
Anti-Obesity Medications in Longevity and Aesthetic Medicine.
Bijoch J
Journal of clinical medicine · 3 Aug 2026
Key finding
Anti-obesity medications (AOMs), led by the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide and the dual GIP/GLP-1 receptor agonist tirzepatide, have produced substantial weight reduction and growing signals of benefit that extend well beyond adiposity. These agents are now discussed in relation to longevity and aesthetic medicine, raising the question of whether
Competitive Landscape
How Retatrutide Compares
Side-by-side reference notes on mechanism, development stage and reported efficacy across leading candidates.
Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.
Retatrutide vs Tirzepatide
Full comparison- Developer
- Eli Lilly and CompanyEli Lilly and Company
- Mechanism
- GLP-1 / GIP / Glucagon triple agonistGLP-1 / GIP dual agonist
- Administration
- Once-weekly subcutaneousOnce-weekly subcutaneous
- Development Stage
- Phase 3Approved (obesity, type 2 diabetes)
- Trial Population
- Obesity ± type 2 diabetesObesity, type 2 diabetes, OSA
- Efficacy Data
- ≈-24% at 48 weeks (Phase 2)≈-21% at 72 weeks (Phase 3)
- Study Duration
- 48–72 weeks72 weeks
- Regulatory Status
- InvestigationalApproved
Retatrutide vs Semaglutide
Full comparison- Developer
- Eli Lilly and CompanyNovo Nordisk
- Mechanism
- GLP-1 / GIP / Glucagon triple agonistGLP-1 receptor agonist
- Administration
- Once-weekly subcutaneousOnce-weekly subcutaneous or oral
- Development Stage
- Phase 3Approved (obesity, type 2 diabetes)
- Trial Population
- Obesity ± type 2 diabetesObesity, type 2 diabetes, CV risk
- Efficacy Data
- ≈-24% at 48 weeks (Phase 2)≈-15% at 68 weeks (Phase 3)
- Study Duration
- 48–72 weeks68 weeks
- Regulatory Status
- InvestigationalApproved
Retatrutide vs CagriSema
Full comparison- Developer
- Eli Lilly and CompanyNovo Nordisk
- Mechanism
- GLP-1 / GIP / Glucagon triple agonistAmylin analogue + GLP-1 agonist
- Administration
- Once-weekly subcutaneousOnce-weekly subcutaneous
- Development Stage
- Phase 3Phase 3 / regulatory submission
- Trial Population
- Obesity ± type 2 diabetesObesity, type 2 diabetes
- Efficacy Data
- ≈-24% at 48 weeks (Phase 2)≈-22% at 68 weeks (Phase 3)
- Study Duration
- 48–72 weeks68 weeks
- Regulatory Status
- InvestigationalInvestigational
Retatrutide vs Amycretin
Full comparison- Developer
- Eli Lilly and CompanyNovo Nordisk
- Mechanism
- GLP-1 / GIP / Glucagon triple agonistAmylin + GLP-1 receptor co-agonist
- Administration
- Once-weekly subcutaneousSubcutaneous or oral (in development)
- Development Stage
- Phase 3Phase 2
- Trial Population
- Obesity ± type 2 diabetesOverweight and obesity
- Efficacy Data
- ≈-24% at 48 weeks (Phase 2)≈-22% at 36 weeks (early phase)
- Study Duration
- 48–72 weeks12–36 weeks
- Regulatory Status
- InvestigationalInvestigational
Retatrutide vs MariTide
Full comparison- Developer
- Eli Lilly and CompanyAmgen
- Mechanism
- GLP-1 / GIP / Glucagon triple agonistGIP receptor antagonist / GLP-1 agonist
- Administration
- Once-weekly subcutaneousMonthly or less frequent subcutaneous
- Development Stage
- Phase 3Phase 3
- Trial Population
- Obesity ± type 2 diabetesObesity, type 2 diabetes
- Efficacy Data
- ≈-24% at 48 weeks (Phase 2)≈-20% at 52 weeks (Phase 2)
- Study Duration
- 48–72 weeks52 weeks
- Regulatory Status
- InvestigationalInvestigational
Pipeline
Next-Generation Obesity Drug Pipeline
The competitive set of incretin, amylin and multi-receptor candidates in late-stage obesity development.
| Drug | Developer | Mechanism | Administration | Phase | Primary Indication | Latest Development | Last Update |
|---|---|---|---|---|---|---|---|
| Retatrutide (LY3437943) | Eli Lilly and Company | GLP-1 / GIP / Glucagon | Weekly subcutaneous | Phase 3 | Obesity | TRIUMPH programme ongoing | Aug 2026 |
| CagriSema | Novo Nordisk | Amylin + GLP-1 | Weekly subcutaneous | Phase 3 | Obesity | Regulatory submissions in progress | Jul 2026 |
| Orforglipron | Eli Lilly and Company | Oral GLP-1 (non-peptide) | Daily oral | Phase 3 | Obesity, type 2 diabetes | Phase 3 readouts reported | Aug 2026 |
| MariTide | Amgen | GIP antagonist / GLP-1 agonist | Monthly subcutaneous | Phase 3 | Obesity | Phase 3 programme initiated | Jun 2026 |
| Amycretin | Novo Nordisk | Amylin + GLP-1 | Subcutaneous / oral | Phase 2 | Obesity | Dose-ranging studies ongoing | Jun 2026 |
| Survodutide | Boehringer Ingelheim / Zealand | GLP-1 / Glucagon | Weekly subcutaneous | Phase 3 | Obesity, MASH | Phase 3 enrolment continuing | May 2026 |
| Petrelintide | Zealand Pharma / Roche | Amylin analogue | Weekly subcutaneous | Phase 2 | Obesity | Phase 2b programme underway | Apr 2026 |
Weekly Briefing
The Retatrutide Report
One concise briefing covering the most important retatrutide clinical trial, research and regulatory developments.
No promotional content. Unsubscribe at any time.